- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held Today at 8:30 am Eastern Time - DEVON, Pa. , Dec.
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 -
DEVON, Pa. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September
DEVON, Pa. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
DEVON, Pa. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher
DEVON, Pa. , July 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host a conference call at 8:30 am EDT on Thursday August 2, 2018
DEVON, Pa. , July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million , before deducting underwriting
DEVON, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference - FAB-C Week 38 - Extension Phase Data: ADAMS Mean Percent Improvement From Baseline FAB-C Week
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa.
DEVON, Pa. , July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying
DEVON, Pa. , May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
DEVON, Pa. , May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure Median Change in Seizure Rates at Months 3, 6, 9 and 12: All ZYN002-treated patients in STAR 2 Median Change in Seizure Rates at Months 3, 6, 9 and 12:
DEVON, Pa. , April 23, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
DEVON, Pa. , April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
DEVON, Pa. , April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders DEVON, Pa. , March 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
DEVON, Pa. , March 22, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
DEVON, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
DEVON, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
Company Expects to Initiate Pivotal Study Mid-Year 2018 and Deliver Top-line Data in 2019 DEVON, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing
- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30 AM Tomorrow , January 4, 2018 - DEVON, Pa. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Zynerba